This roundtable series reviews the use of B-cell maturation antigen–targeted treatments in patients with relapsed/refractory multiple myeloma, as discussed by participants at virtual live events.

BCMA-Targeted Therapy in Patients with Multiple Myeloma

$Part 1: Reviewing Late-Line Options for Relapsed/Refractory Multiple Myeloma$

Part 1: Reviewing Late-Line Options for Relapsed/Refractory Multiple Myeloma

March 30, 2022

During a live virtual event, Faith E. Davies, MD, discussed treatment options for a patient with multiple myeloma who relapsed after multiple lines of treatment including autologous stem cell transplant.

Part 2: Choosing Between BCMA and CAR T-Cell Therapy in Multiple Myeloma

February 04, 2022

During a live virtual event, Natalie Callander, MD, discussed real-world experience with the efficacy of belantamab mafodotin and whether it can be chosen instead of chimeric antigen receptor T-cell therapy.

$Part 1: Selecting Treatment Options for Relapsed/Refractory Multiple Myeloma$

Part 1: Selecting Treatment Options for Relapsed/Refractory Multiple Myeloma

January 26, 2022

During a live virtual event, Natalie Callander, MD, discussed possible treatment options for a patient who relapsed several years after successful treatment of multiple myeloma with bortezomib, lenalidomide, and dexamethasone.